Aizon, a San Francisco AI firm specializing in pharmaceutical manufacturing, has secured $20M in its latest Series C financing. Spearheaded by NewVale Capital and bolstered by key contributors like Atlantic Bridge and Crosslink Capital, Aizon is poised to enhance its AI offerings in drug production.

The infusion of capital signals a robust push to expedite Aizon's product roadmap, promising to deliver innovative solutions to their clientele in the evolving pharma landscape.